Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction

被引:8
|
作者
Axilrod, Andrew C. [1 ]
机构
[1] Hosp Univ Penn, Div Urol, Philadelphia, PA 19104 USA
关键词
Comorbidities; erectile dysfunction; erection; first-dose success; PDE5; inhibitors; vardenafil;
D O I
10.1185/030079907X242656
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Erectile dysfunction (ED) is increasingly being recognized as a sentinel marker of future subsequent cardiovascular disease (CVD). Predicted increases in the prevalence of ED are due to a combination of an aging population and the increasing presence of comorbid conditions (hypertension, dyslipidemia, and diabetes). The dichotomy of the situation is that ED is often associated with these comorbidities, potentially leading to greater CVD risk, and conversely, these comorbidities have also been shown to increase the risk of developing ED. The successful treatment of ED with phosphodiesterase type 5 (PDE5) inhibitor therapy, therefore, is of paramount importance because it not only plays a critical role in restoring erectile function, but also provides clinicians with the opportunity to mitigate existing cardiovascular comorbidities or prevent the occurrence of CVD in this patient population. Methods:This review is based on an electronic literature search of databases, including MEDLINE/PubMed, with information selected for its relevance to PDE5 inhibitor therapy comprising efficacy (e.g., first-dose success) in men with ED with or without comorbidities, onset and duration of action at specific time points, and patient preference. Results: The introduction of PDE5 inhibitors represented a major advance in the treatment of ED. In spite of the availability of these agents, a large percentage of men are still not being treated, in many cases because of their reluctance to seek medical help. Moreover, many men who start treatment with PDE5 inhibitors discontinue treatment. Reasons for discontinuation are many and complex, including lack of initial or first-time success. Although of major concern to both patients and clinicians, there remains limited published clinical data on this specific parameter in the pertinent patient population and from prospective, randomized clinical studies. Conclusion: Data from studies suggests that the available PDE5 inhibitor therapies are effective in treating men with ED, including those who have increased CVD risk and those who have clinically identified cardiovascular comorbidities such as hypertension, dyslipidemia, and/or diabetes. According to data from studies, the attributes of PDE5 inhibitor therapy that matter more to clinicians and patients and that hold influence over treatment compliance include effectiveness in patients with cardiovascular comorbidities, first dose effectiveness or early success, rapid onset of action, reliability, and tolerability.
引用
收藏
页码:3189 / 3198
页数:10
相关论文
共 50 条
  • [31] Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction
    Mulhall, JP
    McLaughlin, TR
    Harnett, JR
    Scott, B
    Burhani, S
    Russell, D
    JOURNAL OF SEXUAL MEDICINE, 2005, 2 (06): : 848 - 855
  • [32] POSSIBLE FUTURE THERAPIES IN PATIENTS WITH ERECTILE DYSFUNCTION NOT RESPONDING TO PHOSPHODIESTERASE TYPE 5 INHIBITORS
    Driesen, K.
    Gonzalez Viedma, A.
    Hofkens, L.
    Philtjens, U.
    Brone, B.
    Sandner, P.
    Van Renterghem, K.
    JOURNAL OF SEXUAL MEDICINE, 2020, 17 (06): : S159 - S160
  • [33] Is there a role for extracorporeal shock wave therapy for erectile dysfunction unresponsive to phosphodiesterase type 5 inhibitors?
    Zou, Zi-jun
    Liu, Zhi-hong
    Tang, Liang-you
    Lu, Yi-ping
    WORLD JOURNAL OF UROLOGY, 2017, 35 (01) : 167 - 171
  • [34] Is there a role for extracorporeal shock wave therapy for erectile dysfunction unresponsive to phosphodiesterase type 5 inhibitors?
    Zi-jun Zou
    Zhi-hong Liu
    Liang-you Tang
    Yi-ping Lu
    World Journal of Urology, 2017, 35 : 167 - 171
  • [35] Efficiency of Combined Therapy with Impaza and Type 5 Phosphodiesterase Inhibitors in Prophylactics of Posttraumatic Erectile Dysfunction
    Ibishev, Kh. S.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2009, 148 (02) : 322 - 324
  • [36] Efficiency of Combined Therapy with Impaza and Type 5 Phosphodiesterase Inhibitors in Prophylactics of Posttraumatic Erectile Dysfunction
    Kh. S. Ibishev
    Bulletin of Experimental Biology and Medicine, 2009, 148 : 322 - 324
  • [37] How to optimise treatment of erectile dysfunction above and beyond the beneficial effects of a phosphodiesterase type 5 inhibitor
    Gooren, Louis
    JOURNAL OF MENS HEALTH, 2008, 5 (02): : 163 - 170
  • [38] Audiometry Results and TEOAE and DPOAE Amplitudes in Men Taking a Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction
    Ontepeli, Sertan
    Muluk, Nuray Bayar
    Tuglu, Devrim
    Sipal, Timucin
    ENT-EAR NOSE & THROAT JOURNAL, 2017, 96 (07) : E34 - E39
  • [39] Efficacy and safety of the phosphodiesterase type-5 inhibitor vardenafil in men with erectile dysfunction and type 1 diabetes mellitus
    Van, Hermann Ahlen
    Merfort, Frank
    Reblin, Tjark
    Neureither, Marcus
    DIABETES, 2006, 55 : A103 - A104
  • [40] TREATMENT OF ERECTILE DYSFUNCTION WITH PHOSPHODIESTERASE TYPE 5 INHIBITOR (PDE5 INH) IN MALE PARTNER OF WOMEN WITH VAGINISMUS
    Ozkara, H.
    Akkus, E.
    Dinc, S.
    Alici, B.
    Tek, B.
    JOURNAL OF SEXUAL MEDICINE, 2011, 8 : 437 - 438